Pharmac’s proposal could expand access to brentuximab vedotin for New Zealanders with systemic anaplastic large cell lymphoma (sALCL), a rare blood cancer.
Pharmac is consulting on expanding brentuximab vedotin to first-line treatment for newly diagnosed sALCL patients, with funding potentially starting April 1, 2026, if approved.
“This would mean people could receive brentuximab vedotin as a first treatment option, instead of waiting until other options have been tried,” Pharmac Manager of Pharmaceutical Funding, Claire Pouwels, said.
“Around 12 people are expected to benefit in the first year, with around 60 people benefitting over the next 5 years.”
Currently, brentuximab vedotin is funded only for relapsed or refractory sALCL cases. Earlier access could improve outcomes for patients facing poor survival rates and high health needs.
“Systemic anaplastic large cell lymphoma is a rare cancer that is often diagnosed in people under 55,” Pouwels explained.
“Making this treatment available earlier has the potential to improve both survival and quality of life.”
Meanwhile, Health Ministers David Seymour and Simeon Brown welcome Pharmac’s proposal.
“Improving access to cancer medication in New Zealand is important to cancer patients and their families. That’s why it has been a focus of this government,” Seymour said.
Pharmac invites feedback from sALCL patients, whānau, health professionals, advocacy groups, and others until 5 pm, February 19, 2026.